Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: COX-2 modulates mammary tumor progression in response to collagen density

Fig. 2

Celecoxib diminishes PyMT/Col1a1, but not PyMT, tumor growth. a Timeline for the celecoxib therapeutic study. See “Methods” for more details. b Representative example of tumors arising in collagen-dense mice treated with vehicle or celecoxib. c Quantitation of several tumors from mice treated with vehicle or celecoxib. Tumor weight is higher in PyMT/Col1a1 tumors when compared to PyMT tumors. Celecoxib delays tumor growth in mice with collagen-dense tumors. d Immunohistochemical analysis (IHC) of representative tumor sections stained with antibody against Ki-67 (visualized with 3,3-diaminobenzidine (DAB) (brown)) and counterstained with hematoxylin; ×20 objective; scale bar = 100 um. e Quantitation of the number of Ki67-positive cells normalized to the total number of cells. Celecoxib treatment diminishes proliferation levels as measured with the Ki-67 marker in both PyMT and PyMT/Col1a1 tumors. Veh vehicle, Clxb celecoxib. Raw data depicted; *p < 0.05, **p < 0.01, ****p < 0.0001; n = 5 mice; at least 8 image fields analyzed per 2–3 tumors per animal

Back to article page